Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Assets Average (2016 - 2025)

Ligand Pharmaceuticals' Assets Average history spans 15 years, with the latest figure at $1.2 billion for Q3 2025.

  • For Q3 2025, Assets Average rose 33.17% year-over-year to $1.2 billion; the TTM value through Sep 2025 reached $1.2 billion, up 33.17%, while the annual FY2024 figure was $864.5 million, 11.56% up from the prior year.
  • Assets Average for Q3 2025 was $1.2 billion at Ligand Pharmaceuticals, up from $927.0 million in the prior quarter.
  • Across five years, Assets Average topped out at $1.3 billion in Q1 2021 and bottomed at $763.7 million in Q3 2023.
  • The 5-year median for Assets Average is $927.0 million (2025), against an average of $1.0 billion.
  • The largest annual shift saw Assets Average tumbled 34.5% in 2023 before it skyrocketed 33.17% in 2025.
  • A 5-year view of Assets Average shows it stood at $1.3 billion in 2021, then decreased by 29.48% to $906.6 million in 2022, then decreased by 14.16% to $778.2 million in 2023, then grew by 21.86% to $948.3 million in 2024, then increased by 27.88% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for LGND's Assets Average are $1.2 billion (Q3 2025), $927.0 million (Q2 2025), and $923.6 million (Q1 2025).